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 Carcinoma cells, including breast cancer,  develop in a complex and dynamic microenvironment where the tumor 
cells are embedded in a supporting framework composed of tissue specific types of extracellular matrix (ECM), different 
cellular components including fibroblasts, lymphatics, vasculatures including endothelial cells, inflammatory cells and 
others and various kinds of cytokines. Tumor-stroma reciprocal cellular pathways, interactions and crosstalks play 
indispensible roles in tumorigenesis, development, disease progression, subsequent invasion and metastasis, and also in 
determining the therapeutic response.  This tumor stroma micro-mileu hence is generally considered an imperative and 
integrated part of the solid cancer development and progression.  
	 Neoangiogenesis and tumor infiltrative lymphocytes (TIL) are two important stromal components as stated above.  It 
is therefore important to evaluate the effects of different therapeutic agents upon the tumor stroma, which could provide 
new insights into how breast carcinoma responds or why the state of clinical resistance to a particular treatment 
developed in the treated patients with breast cancer.  Therefore, in this study, I assessed the effects of different 
therapeutic agents upon the tumor micro-milieu, with particular emphases on the tumor neoangiogenesis and infiltrative 
lymphocytes.  The differences in the changes of neoangiogenesis and TIL subtypes in response to neoadjuvant AI and 
chemotherapy as reported in my present studies did firstly demonstrate that not only the tumor cells but also other cells 
in the tumor stroma microenvironment (neoangiogenesis and TIL in this respect) responded differently to the therapeutic 
agents as reflected by the change in mitotic index in the AI group and the histopathological changes of cytotoxic effects 
in the chemotherapy group. 
	 Considering the complex reciprocal interactions and cross-talks among different cellular pathways of carcinoma cells 
and their microenvironment, these results here in my study clearly indicated that not only features of carcinoma cells but 
also those of adjacent stromal cells in the tumor microenvironment should be incorporated when assessing the response 
to any therapeutic agent given.  The importance of considering the carcinoma cells and tumor microenvironment as a 
whole in the treatment of breast cancer was clearly confirmed in my present study. 
 
